

# Neuroscience Grand Rounds 2026

## Update on Repurposing of Sub-Anesthetic Ketamine to Treat L-DOPA-Induced Dyskinesia (LID)

March 20, 2026 – 8:00 AM

### Overall Activity Objectives:

- 1 Incorporate into practice current evidence-based practices to get patients with stroke the most appropriate treatment/intervention in the shortest time possible.
- 2 Incorporate disease modifying therapies into the treatment plan for individuals with multiple sclerosis based on the most current clinical research and professional society guidelines and the underlying science regarding mechanism of action.
- 3 Evaluate patients with neuromuscular disease for the use of the latest treatments, based on evidence-based guidelines and publications.
- 4 Treat patients with migraine with the latest agents and strategies when traditional treatments fail.
- 5 Refer patients with Parkinson's disease and other movement disorders for neuromodulatory treatments sooner in their treatment paradigm.
- 6 Incorporate ethical constructs into the delivery of care and communication with patients and their families.

### Session Objectives:

- 1 To understand the pathological characteristics and symptoms of Parkinson's Disease and Levodopa-induced dyskinesia.
- 2 To learn about the mechanisms underlying the lasting anti-dyskinetic action of low-dose ketamine in the pre-clinical model.
- 3 To understand the clinical potential of repurposing low-dose ketamine for individuals with Parkinson's Disease.

### Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

| Name of individual   | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|----------------------|-------------------------------|---|
| Amanda A Codling, MD | Planning Committee Member     | Nothing to disclose - 12/04/2025                          |
| Micah Etter, MD      | Planning Committee Member     | Nothing to disclose - 10/29/2025                          |

|                         |                           |  |
|-------------------------|---------------------------|--|
| Torsten Falk, PhD       | Faculty                   | Royalties or Patent Beneficiary-Teleport Pharmaceuticals, LLC, a UA startup Royalties or Patent Beneficiary-PharmaTher Inc. Paid consultant-PharmaTher Inc. (Relationship has ended) Honoraria-PharmaTher Inc. (Relationship has ended) - 03/10/2026 |
| Dedrick Jordan, MD, PhD | Activity Director         | Other: Data Safety Monitoring Board-Acasti Pharma (Relationship has ended) Paid consultant-Novo Nordisk (Any division) Paid consultant-Icon PLC - 02/27/2026   |
| David M Labiner, MD     | Planning Committee Member | Grant or research support-Neurona Therapeutics Grant or research support-Xenon - 10/29/2025  |



THE UNIVERSITY OF ARIZONA

College of Medicine

Tucson